XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the development of orally-available drugs for the treatment of autoimmune diseases. The company’s lead product candidate, hCDR1, has shown promising results in clinical trials and has the potential to address significant unmet medical needs in conditions such as systemic lupus erythematosus and Sjögren’s syndrome. With a strong pipeline and innovative approach, XTL Biopharmaceuticals is well-positioned for future growth in the biopharmaceutical industry.
- Latest
- Trending
